ReviewJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi2021
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
Review in Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.Biomedicines · 2025Article
- Clinical outcomes and considerations in outpatient with COVID-19 receiving remdesivir therapy.Health science reports · 2024Article
- Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza.BMC medicine · 2023Article
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.Journal of medical virology · 2023Review
- Disparate viral pandemics from COVID19 to monkeypox and beyond: a simple, effective and universal therapeutic approach hiding in plain sight.Frontiers in immunology · 2023Review
- Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021.Journal of the Formosan Medical Association = Taiwan yi zhi · 2022Article
- Amphiphilic anti-SARS-CoV-2 drug remdesivir incorporates into the lipid bilayer and nerve terminal membranes influencing excitatory and inhibitory neurotransmission.Biochimica et biophysica acta. Biomembranes · 2022Article
- Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.Journal of clinical epidemiology · 2022Article
- Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022Review
- Cuttlefish bone powder as an efficient solid-phase extraction sorbent of anti-SARS-CoV-2 drugs in environmental water.Chemicke zvesti · 2022Article
- Kidney injury in COVID-19 patients, drug development and their renal complications: Review study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.Clinical and translational science · 2021Article
- Article
- Mechanism and adverse effects of COVID-19 drugs: a basic review.International journal of physiology, pathophysiology and pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.